MEDNAX Inc (NYSE:MD) Shares Sold by Treasurer of the State of North Carolina

Share on StockTwits

Treasurer of the State of North Carolina cut its position in shares of MEDNAX Inc (NYSE:MD) by 4.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 41,314 shares of the company’s stock after selling 1,840 shares during the quarter. Treasurer of the State of North Carolina’s holdings in MEDNAX were worth $1,042,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of MD. Riverhead Capital Management LLC increased its position in MEDNAX by 97.1% during the first quarter. Riverhead Capital Management LLC now owns 128,689 shares of the company’s stock worth $3,496,000 after buying an additional 63,413 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of MEDNAX by 90.5% in the second quarter. Acadian Asset Management LLC now owns 567,153 shares of the company’s stock valued at $14,310,000 after purchasing an additional 269,468 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of MEDNAX by 1,401.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 147,900 shares of the company’s stock valued at $3,732,000 after purchasing an additional 138,050 shares during the period. Canada Pension Plan Investment Board grew its position in shares of MEDNAX by 35.4% in the second quarter. Canada Pension Plan Investment Board now owns 262,619 shares of the company’s stock valued at $6,626,000 after purchasing an additional 68,691 shares during the period. Finally, Aperio Group LLC grew its position in shares of MEDNAX by 69.5% in the second quarter. Aperio Group LLC now owns 104,435 shares of the company’s stock valued at $2,635,000 after purchasing an additional 42,838 shares during the period. 92.26% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of MEDNAX stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $20.81, for a total value of $104,050.00. Following the transaction, the director now owns 15,821 shares in the company, valued at $329,235.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Fernandez bought 122,409 shares of MEDNAX stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $21.35 per share, for a total transaction of $2,613,432.15. Following the acquisition, the director now directly owns 350,288 shares of the company’s stock, valued at approximately $7,478,648.80. The disclosure for this purchase can be found here. 3.40% of the stock is currently owned by company insiders.

MD has been the subject of a number of recent analyst reports. Bank of America downgraded MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price objective for the company. in a research report on Friday, September 6th. Mizuho lowered their price objective on MEDNAX from $26.00 to $24.00 and set a “neutral” rating for the company in a research report on Friday, August 2nd. UBS Group lowered their price objective on MEDNAX to $20.00 and set a “sell” rating for the company in a research report on Wednesday, July 24th. BMO Capital Markets lowered their price objective on MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a research report on Monday, August 5th. Finally, Credit Suisse Group lowered their price objective on MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a research report on Tuesday, August 27th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $28.30.

Shares of NYSE:MD opened at $21.55 on Friday. The company has a market cap of $1.79 billion, a P/E ratio of 6.14, a P/E/G ratio of 0.82 and a beta of 0.73. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.79. MEDNAX Inc has a 52 week low of $19.93 and a 52 week high of $46.21. The business has a fifty day simple moving average of $22.08 and a 200-day simple moving average of $24.73.

MEDNAX (NYSE:MD) last issued its earnings results on Thursday, August 1st. The company reported $0.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.11. MEDNAX had a positive return on equity of 9.34% and a negative net margin of 3.53%. The firm had revenue of $868.31 million for the quarter, compared to analysts’ expectations of $868.71 million. During the same quarter last year, the firm earned $1.07 earnings per share. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. Sell-side analysts expect that MEDNAX Inc will post 3.04 earnings per share for the current fiscal year.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Recommended Story: What does an inverted yield curve signify?

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.